International Journal of Hematology

Article	Citations
Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma	98
Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib	83
Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature	61
Coexpression of natural killer cell antigens by T-cell large granular lymphocytes in hydroa vacciniforme lymphoproliferative disorder and the involvement of Vδ1 + epithelial-type γδT cells	41
Post-transfusion purpura and adult primary thrombocytopenia	37
CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment	30
Changes in coagulation potential over time after administration of recombinant activated factor VII in an emicizumab-treated hemophilia A patient with inhibitors	27
WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia	27
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice	25
Advances in immune microenvironment profiling during multiple myeloma progression and therapy	24
Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST	23
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era	21
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study	20
Carcinocythemia diagnosed on peripheral blood clot sections	20
Acute megakaryoblastic leukemia with RBM15::MKL1 fusion presenting as neonatal acute liver failure: rescued by living-donor liver transplantation	20
Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort	19
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma	19
Ten years’ experience in prenatal diagnosis of α-thalassemia in a municipal hospital and retrospective analysis of ultrasonic abnormalities	18
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells	18
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets	18
Recent progress in T-cell malignancies including adult T-cell leukemia–lymphoma	18
SPAG6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia	17
Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A	17
Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome	16
BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis	16

Chemotherapy-induced aseptic thrombophlebitis with an air bubble in the thrombus	16
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia	16
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)	16
Effects of human herpesvirus 6B reactivation on cognitive function in cord blood transplant recipients: a prospective multicenter study	15
Primary pancreatic diffuse large B-cell lymphoma, appearing as an asymptomatic bulky mass with the duct-penetrating sign	15
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy	15
Recent advances in CAR T and CAR NK cell therapy for AML	14
HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA	14
Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma	13
Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis	13
Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma	13
Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan	13
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia	13
Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia	13
Micafungin-induced hemolytic anemia: a case report and investigation of anti-micafungin antibody prevalence	13
Some key considerations regarding the design and evaluation of high-throughput sequencing-based biallelic chimerism assays	13
Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors	13
JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview	12
Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation	12
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma	12
Retrospectively diagnosed autoimmune VWF deficiency in a patient with repeated hemorrhagic events after two common colds	12
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)	12
Evolution and optimization of therapies for acute lymphoblastic leukemia in infants	12
Validation of an algorithm for identifying patients with febrile neutropenia: an epidemiological study using real-world data in Japan	11
Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia	11
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia	11
Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)	11
Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies	11
Guest Editorial: what can be done to improve cancer immunotherapies?	11
Nodal mature plasmacytoid dendritic cell proliferation mimicking lymphoma in a patient with CALR-mutated myelofibrosis	11
DLI-induced remission in recurrent EBV-associated T/NK-cell lymphoproliferative disease following HSCT: a case report	11
Effect of delivery mode on postnatal platelet count dynamics in neonates born to mothers with immune thrombocytopenia	11
Combined tumor necrosis factor-α (−308 G/A) and tumor necrosis factor-β (+ 252 A/G) nucleotide polymorphisms and chronicity in Egyptian children with immune thrombocytopenia	10
Evaluation of Real-world treatment patterns in Japanese patients with cGVHD: A retrospective claims database study	10
Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma	10
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome	10
Multiple myeloma with high-risk cytogenetics and its treatment approach	10
Assay variables and early clinical evaluation of low-angle light scattering for platelet function analysis	10
Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemia	10
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023	10
Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach	9
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit	9
Clinical features of immature leukemias in children	9
Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions	9
Detection of Talaromyces marneffei in a HIV-infected patient from peripheral blood observation through Sysmex XN WNF/WNR channels	9
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants	9
An adult case of refractory autoimmune neutropenia after liver transplantation	9
Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation	9
Therapy-related acute myeloid leukemia with inv(16)(p13.1q22)	9
Auer rods in mature granulocytes in peripheral blood	9

Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system	8
Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia	8
Clinicopathological characteristics associated with the engraftment of patient lymphoma cells in NOG mice	8
Epidemiological survey of potential familial myelodysplastic syndromes/acute myeloid leukemia in Hawaii	8
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia	8
A phase 2 trial of VRD induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma	8
Long-term efficacy and safety profile of splenectomy for pediatric chronic immune thrombocytopenia	8
A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and PAX5 mutation	8
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)	8
Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma	8
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia	8
Prognostic significance of age at diagnosis and preceding infection varies across age groups in childhood immune thrombocytopenia	8
Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database	8
Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort	8
Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients	7
Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era	7
Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia	7
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS	7
Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag	7
Hematopoietic cell transplantation in pediatric EB virus-associated hemophagocytic lymphohistiocytosis	7
Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid	7
Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia	7
Resilient T-cell responses in patients with advanced cancers	7
Pseudo-Chediak–Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia	7
Sarcopenia and clinical outcomes in lymphoma and multiple myeloma patients receiving hematopoietic cell transplantation: a systematic review and meta-analysis	7
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study	7
A retrospective survey of patients who discontinued participation in the JPLSG HLH-2004 clinical trial	7
Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency	7
Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis	7
Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation	7
Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy	7
Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction	7
Leukemic-phase mucosa-associated lymphoid tissue lymphoma	7
Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation	7
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia	7
Correction: Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series	7
JSH practical guidelines for hematological malignancies, 2023: leukemia-2—acute promyelocytic leukemia (APL)	7
Characterization of congenital factor XII deficiency in Taiwanese patients: identification of one novel and one common mutation	7
Association of busulfan area under the curve with the development of neurotoxicity in children and adolescents receiving busulfan-containing conditioning regimens for stem cell transplantation	7
Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms	7
A rare case of concurrent metastatic breast cancer and follicular lymphoma diagnosed by lymph node biopsy: a case report	7
Bilateral development of biclonal ocular adnexal marginal zone lymphoma at a 2-year interval	6
Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB	6
Japanese and French translation and linguistic validation of a patient-reported outcome tool to assess quality of life in patients with Immune Thrombocytopenia (ITP): the ITP Life Quality Index (ILQI)	6
TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia	6
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura	6
Ten-color multicolor flow cytometry-based measurable residual disease at pre-transplantation predicts relapse of acute myeloid leukemia: a prospective study	6
Recent advances in understanding the biology of follicular lymphoma	6
Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient	6
FNAIT pathogenesis determined by serial analysis of three subsequent pregnancies of a woman with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT) with anti-HPA-4b and anti-HPA-5b alloanti	6
A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion	6
Dysregulated hemostasis in acute promyelocytic leukemia	6
Longer-than-expected survival in TP53-mutated MDS with der(5;19)(p10;q10): lessons from three cases	6
Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation	6
Outcome of chemotherapy dose reduction in overweight Japanese children with acute lymphoblastic leukemia	6
FLT3 targeting in the modern era: from clonal selection to combination therapies	6
HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia	6
Spontaneous regression of multiple solitary plasmacytoma harboring Epstein–Barr virus: a case report and literature review	6
The mutual crosstalk between iron and erythropoiesis	6
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review	6
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marke	6
Management of lymphoma-associated chylothorax by interventional radiology and chemotherapy: a report of five cases	6
A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution	6
Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors	6
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis	6
Guest editorial: recent progress in pediatric leukemia	6
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma	5
Successful autologous stem cell transplantation in a case of central nervous system relapse of diffuse large B-cell lymphoma with concurrent polycythemia vera	5
Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes	5
Massive pleural effusion as the initial presentation of Waldenström macroglobulinemia: rare extramedullary involvement	5
Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis	5
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 4. Mantle cell lymphoma (MCL)	5
Recent advances in AML with mutated NPM1	5
VEXAS syndrome	5
Correction to: Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	5
Pneumatic tube transport-induced pseudohyperkalemia in patients with extreme leukocytosis: a retrospective study from a single medical center	5
Reply to the Dr. Murphy’s comment	5
Correction: Real‑world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis o	5
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease	5

In vitro evaluation of global coagulation potential of emicizumab and warfarin using rotational thromboelastometry	5
Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries	5
Efficacy of alternate day versus daily oral iron therapy in children with iron deficiency anemia: a randomized controlled trial.	5
A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria	5
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)	5
Thrombophagocytosis by myeloid blasts in acute myeloid leukemia with biallelic CEBPA mutations	5
MYC-rearranged blastic plasmacytoid dendritic cell neoplasm with immunoblastoid features	5
Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples	5
Novel immunotherapies in multiple myeloma	5
Mature T-cell and NK-cell lymphomas: updates on molecular genetic features	5
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM	5
Heme as a differentiation-regulatory transcriptional cofactor	5
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes	5
Disease burden and treatment patterns of paroxysmal nocturnal hemoglobinuria in Japan: a real-world survey	5
Stem cell regulation and dynamics in myeloid malignancies	5
Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution	5
A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia	5
A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis	5
A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review	5
Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan	5
Factor XII deficiency: a clinical and molecular genetic study	5
Bronchiolitis obliterans complicating follicular lymphoma: a case series and clinical insights	5
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio	5
Decreased incidence of acute immune thrombocytopenia in children during the COVID-19 pandemic	5
Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2—acute promyelocytic leukemia (APL)	5
Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report	5
Identification and functional analysis of three novel genetic variants resulting in premature termination codons in three unrelated patients with hereditary antithrombin deficiency	5
Clinical diagnostic accuracy of respiratory failure in critically ill hematopoietic stem cell transplant patients	5
Septic shock caused by Capnocytophaga canimorsus in a patient with heterozygous Pelger-Huët anomaly	5
Anakinra for the treatment of adult secondary HLH: a retrospective experience	5
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination	5
Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation	5
Recent advances in the pathophysiology and treatment of GVHD	4
Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group	4
Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?	4
Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation	4
JSH Practical Guidelines for Hematological Malignancies, 2023: II. Lymphoma—2. Marginal zone lymphoma: MZL (extranodal marginal zone lymphoma: EMZL [extranodal marginal zone lymphoma of mucosa associa	4
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease	4
Correction: JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML)	4
Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission	4
Long-range and real-time PCR identification of a large SERPINC1 deletion in a patient with antithrombin deficiency	4
Impact of muscle loss in children with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation	4
Knockdown of the Shwachman-Diamond syndrome gene, SBDS, induces galectin-1 expression and impairs cell growth	4
Peripartum management of hereditary thrombophilia: results of primary surveillance in Japan	4
Immunohistochemical differentiation of extramedullary acute myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm	4
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1	4
Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma	4
Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction	4
Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma	4
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia	4
Platelet and large platelet ratios are useful in predicting severity of COVID-19	4
Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation	4
A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma	4
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study	4
Late renal, liver, endocrine, and cardiac outcomes of bone marrow transplantation in Kurdish children with β-thalassemia major	4
Impact of center volume on acute graft versus host disease in allogeneic stem cell transplant recipients	4
Blasts engulfing erythrocytes: an unusual morphological finding in adult early T-precursor acute lymphoblastic leukemia	4
Safety and efficacy of clofarabine for preconditioning intervention in patients undergoing allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphoblastic leukemia	4
Effect of conditioning intensity on late complications in AYA who underwent allogeneic HCT during childhood	4
Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by 18F-FLT PET imaging	4
Philadelphia chromosome–negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study	4
Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation	4
Epigenetic regulation by ASXL1 in myeloid malignancies	4
Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review	4
Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review	4
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line	4
Measurement of serum hepcidin-25 by latex agglutination in healthy volunteers and patients with hematologic disorders	4
JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 2. Related disorders of multiple myeloma	4
Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma	4
Genome–epigenome crosstalk in T-cell lymphomas: from maps to mechanisms	4
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine–bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma	4
Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia	4
Multifocal osteonecrosis after stem cell transplantation	4
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation	4
Very early death within 30 days after diagnosis in patients with acute myeloid leukemia	4
Iliopsoas haemorrhage complicated by femoral neuropathy in patients with haemophilia: a case series report	4
Long-term immunity to measles and rubella after vaccination in adult allogeneic hematopoietic stem cell transplant recipients	4
Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era	4
Comprehensive assessment of DeVIC therapy for relapsed or refractory diffuse large B-cell lymphoma	4
Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations	4